Regeneron (REGN, $324.94) misses Q1 earnings and revenue estimates
Regeneron Pharmaceuticals’ first-quarter earnings came in lower than what analysts expected.
Regeneron raked in adjusted earnings of $4.45 per share, missing Wall Street's expectation of $5.52. Revenue of $1.71 billion also was lower than analysts' $1.76 billion expectations.
CEO Leonard Schleifer emphasized that the company is optimistic about the potential of its product Dupixent, which is now FDA-approved in atopic dermatitis and asthma in both adults and adolescents and is currently under Priority Review by the FDA for chronic rhinosinusitis with nasal polyps.
REGN's Stochastic Oscillator sits in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Show more
Notable companies
The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Nektar Therapeutics (NASDAQ:NKTR).
Industry description
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Market Cap
The average market capitalization across the Biotechnology Industry is 2.98B. The market cap for tickers in the group ranges from 151 to 584.45B. NONOF holds the highest valuation in this group at 584.45B. The lowest valued company is MYMX at 151.
High and low price notable news
The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was -4%. ORKA experienced the highest price growth at 872%, while ATHA experienced the biggest fall at -82%.
Volume
The average weekly volume growth across all stocks in the Biotechnology Industry was -9%. For the same stocks of the Industry, the average monthly volume growth was -48% and the average quarterly volume growth was -29%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 61
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: -28 (-100 ... +100)